Domov › Burkittov limfom › New York › New York City

Klinične študije za Burkittov limfom v New York City, NY

13 študij za Burkittov limfom išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 3

Memorial Sloan Kettering Cancer Center, New York

Starost 1 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07223021

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
in še 1

366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 3

Mount Sinai Hospital, New York
NYP/Weill Cornell Medical Center, New York

Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Vključevanje udeležencevFaza 2

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Vključevanje udeležencevFaza 3

David H. Koch Center for Cancer Care, New York

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Vključevanje udeležencevFaza 1/2

Memorial Sloan Kettering Cancer Center ( Site 1010), New York

6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 1

Columbia University Irving Medical Center/New York Presbyterian Hospital, New York

Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
NYP/Weill Cornell Medical Center, New York

Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Vključevanje udeležencevFaza 3

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Mount Sinai Hospital, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
in še 2

365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085